Serotonin, a critical neurotransmitter deeply involved in mood regulation, cognition, and circadian rhythms, is substantially implicated in non-motor symptoms of PD. The brainstem’s raphe nuclei (RN) house serotonergic neurons that project widely to cortical and subcortical brain regions. The pathological accumulation of α-syn in these nuclei during early Braak stages signifies a prelude to early non-motor manifestations of PD, such as depression, occurring well before the onset of classical motor symptoms linked to dopaminergic neuronal loss. Imaging and postmortem analyses corroborate the selective vulnerability and substantial loss of serotonin transporter binding and serotonergic neurons in PD, underscoring a mechanistic basis for prodromal depressive symptoms stemming from direct α-syn-induced serotonergic dysfunction.

Experimental animal models have provided mechanistic insights, revealing that overexpression of human wild-type α-syn in serotonergic neurons leads to aggregation, impaired brain-derived neurotrophic factor (BDNF) production, disrupted serotonin neurotransmission, and related depressive-like behaviors. Remarkably, targeted suppression of α-syn synthesis in these cells reverses these deficits, highlighting α-syn as a modifiable factor in the neuropsychiatric dimension of PD. This points to a model in which α-syn pathology is not merely a downstream consequence but an active driver of depression through serotonergic circuit impairment.

Dopaminergic transmission disturbances remain a hallmark of PD pathophysiology, further entangling the relationship between PD and depression. Beyond the loss of substantia nigra dopamine neurons, reductions in dopamine transporter (DAT) availability have been observed in depressed individuals, although receptor availability differences remain inconclusive. Stress-induced hypercortisolemia exacerbates α-syn aggregation and dopaminergic neuronal loss, likely mediated through toxic dopamine metabolites such as DOPAL, which foster α-synuclein misfolding and mitochondrial perturbations. These findings expose a vicious cycle wherein psychological stress and α-syn aggregation coalesce to deteriorate dopaminergic circuits, thereby driving both motor and affective symptoms.

The impact of α-syn extends into the noradrenergic domain, with norepinephrine (NE) depletion emerging early in PD brainstem pathology. Loss of locus coeruleus-derived NE, mirroring alterations in dopamine and serotonin systems, has been linked to cognitive, autonomic, and mood dysfunctions in PD. Intriguingly, α-syn modulation of NE transporter trafficking via microtubule interactions adds a layer of complexity, suggesting that aberrant α-syn can directly interfere with NE signaling. Clinically, NE reuptake inhibitors have demonstrated efficacy in ameliorating depressive symptoms in PD without improving motor deficits, indicating neurotransmitter-specific therapeutic avenues.

Neuroinflammation serves as a convergent mechanism exacerbating both PD and depression pathology. Chronic stress and hypothalamic-pituitary-adrenal (HPA) axis dysfunction reduce glucocorticoid receptor (GR) efficacy, undermining microglial and astrocytic control over inflammatory responses. This loss catalyzes relentless production of pro-inflammatory cytokines and glial activation. Crucially, studies show that restoring GR signaling mitigates α-syn accumulation and dopaminergic neuron loss by modulating key inflammatory pathways such as NFκB and TLR9. Additionally, α-syn’s pathological interaction with microglial purinergic receptors like P2X7 amplifies mitochondrial dysfunction and neuroinflammation. These findings suggest that neuroinflammatory escalation driven by α-syn and stress-induced GR dysregulation fuels a destructive feedback loop worsening PD outcomes.

Altered synaptic plasticity also emerges as a critical interface between stress, α-syn, and PD progression. Psychosocial stress influences dopaminergic receptor availability and synaptic proteins in PD models, suggesting vulnerability of plasticity-related mechanisms to chronic corticosterone exposure. Concurrently, α-syn exhibits a dual role in modulating dopamine release, inducing activity-dependent facilitation followed by suppression, contributing to synaptic dysregulation. Although the detailed molecular crosstalk involving glucocorticoids, GRs, and α-syn in synaptic plasticity remains to be elucidated, these dynamics likely potentiate the emergence of affective symptoms and accelerate neural circuit degenerations.

Mitochondrial dysfunction, a converging hallmark of neurodegenerative and mood disorders, profoundly intersects with α-syn pathology. Synergistic toxicity induced by concurrent corticosterone and neurotoxic insults exacerbates oxidative stress, depletes antioxidant defenses, and impairs mitochondrial respiration, particularly within the substantia nigra. Furthermore, α-syn aggregation driven by reactive oxygen species fosters a pernicious cycle of mitochondrial membrane disruption and energy failure. Despite gaps in understanding the modulation of these processes by glucocorticoid signaling, the intimate link between mitochondrial impairment and α-syn propagation constitutes a key pathological axis in PD-depression comorbidity.

Apoptotic pathways influenced by α-syn and diminished neurogenesis further erode neuronal integrity. The hippocampus, a rare site of adult neurogenesis, relies heavily on BDNF signaling for neuronal survival, plasticity, and differentiation. Genetic variants reducing BDNF expression substantially elevate depression risk in PD and correlate with motor symptom severity. α-Syn overexpression disrupts BDNF production, serotonergic innervation, and key synaptic proteins within hippocampal circuits, precipitating depressive phenotypes that precede motor decline. Pharmacological modulation restoring BDNF levels demonstrates symptomatic improvement, underscoring the centrality of trophic support loss in PD-associated depression.

Emerging evidence implicates serum and glucocorticoid-regulated kinase 1 (SGK1) as a modulator of apoptosis and α-syn accumulation, though conflicting patterns of its expression in depression and PD models temper conclusive interpretations. Similarly, other apoptosis-related mediators with glucocorticoid receptor elements, such as BCL2, warrant deeper investigation within PD-depression frameworks. Mitochondrial-related apoptotic signaling compounds this vulnerability, highlighting multiple overlapping mechanisms driving neuronal loss.

At a genomic level, integrated analyses of GWAS data reveal shared genetic loci linking PD patients with SNCA polymorphisms and individuals with major depressive disorder. Notable shared genes include DYRK1A, known for phosphorylating α-syn and promoting dopaminergic and serotonergic neuronal death, and HLA-DRB1 and HLA-DQA1, which facilitate α-syn presentation to immune cells, fostering inflammation. The vitamin D receptor pathway materializes as a significant genetic susceptibility axis, presenting potential targets for therapeutic intervention aimed at mitigating exacerbated pathology when depression and PD coexist.

Complementing this genetic overlap, transcriptomic meta-analyses identify a set of differentially expressed genes equally perturbed in PD and depression, predominantly involved in innate immune activation and intrinsic apoptotic signaling. Although expression changes are modest, these reflect sustained low-grade inflammation and neurodegenerative processes, possibly potentiated by α-syn dysregulation in vulnerable brain regions.

Collectively, these multi-faceted data converge on the conceptualization of α-synuclein as a critical molecular bridge between Parkinson’s disease and depression. The bidirectional pathology, encompassing neurotransmitter disruptions, neuroinflammation, synaptic dysfunction, mitochondrial impairment, and impaired neurogenesis, underscores the complexity of the PD-depression interface. Targeting α-syn and its interconnected pathways offers a promising paradigm for earlier diagnosis, refined stratification, and novel therapeutic strategies that address both motor and affective symptoms, potentially altering the course of this debilitating dual affliction.

This integrative perspective not only reshapes our understanding of Parkinson’s disease beyond its motor phenotype but also elevates depression from a mere comorbidity to an intrinsic component of PD pathology. Future research harnessing longitudinal, mechanistic, and interventional approaches is imperative to unravel the intricacies of α-syn’s role, transforming patient care through precision medicine tailored to this devastating neuropsychiatric synergy.

Subject of Research:
Investigating the molecular and genetic interplay of α-synuclein in Parkinson’s disease and depression, with a focus on shared pathogenic mechanisms.

Article Title:
α-synuclein in Parkinson’s disease: a central point of convergence with depression.

Article References:
Yusuf, A.M., Ilce, B.Y., Alhaj, H.A. et al. α-synuclein in Parkinson’s disease: a central point of convergence with depression. npj Parkinsons Dis. 11, 329 (2025). https://doi.org/10.1038/s41531-025-01167-w

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41531-025-01167-w

Among these proteins, amyloid-β has been extensively studied due to its central role in Alzheimer’s disease. The aggregation of Aβ into fibrillar structures is associated with neurotoxic effects that lead to synaptic dysfunction and ultimately neuronal death. The significance of imaging technologies, particularly positron emission tomography (PET), has revolutionized our understanding of Aβ deposition. This imaging modality now allows researchers and clinicians to visualize Aβ accumulation throughout the progression of Alzheimer’s disease. With ongoing advancements in PET technology, it is increasingly feasible to monitor responses to therapies aimed at targeting amyloid-β, although challenges remain regarding the detection of specific Aβ assembly subspecies.

In addition to Aβ, tau protein has garnered attention for its critical involvement in various neurodegenerative disorders. The formation of tau tangles, another hallmark of Alzheimer’s disease, is a central focus of current research. Various PET radiotracers have been developed to detect tau deposits, enabling researchers to distinguish between Alzheimer-type tau pathology and non-Alzheimer-associated tau aggregates. A deeper understanding of the binding mechanisms of these radiotracers, as revealed by high-resolution imaging techniques like cryo-electron microscopy, is shedding new light on the structural nuances of tau fibrils and enhancing the specificity of tau imaging.

Moreover, α-synuclein has been at the forefront of research into Parkinson’s disease and multiple system atrophy. The development of high-contrast PET imaging techniques for visualizing α-synuclein lesions has marked a notable advancement in neuroimaging. This progress holds promise for diagnosing these conditions at earlier stages, thereby improving patient management and treatment outcomes. Despite these advancements, there remains a wealth of α-synuclein pathologies that are less prevalent and more challenging to visualize. Continued exploration in this area is essential to broaden our understanding of the diverse manifestations of synucleinopathies.

TDP43 and FUS represent additional proteins whose misfolding and aggregation are associated with neurodegenerative diseases. The detection of these protein aggregates through imaging techniques poses unique challenges due to their lower prevalence compared to amyloid-β and tau. However, innovative public–private partnerships focused on biomarker development may provide the momentum needed to address these hurdles. By fostering collaborations among academic institutions, pharmaceutical companies, and biotech firms, there is immense potential to accelerate the discovery of reliable imaging agents for TDP43 and FUS.

As the landscape of neurodegenerative disease research evolves, the integration of advanced imaging techniques into clinical practice is becoming increasingly valuable. PET imaging helps to not only visualize the presence of pathological protein aggregates but also to assess their dynamic changes over time in response to therapeutic interventions. This capability transforms the traditional methods of diagnosing neurodegenerative diseases, providing a window into the underlying biological processes.

The significance of this research extends beyond diagnostic applications. Understanding the dynamics of protein aggregates through advanced imaging can pave the way for developing targeted therapies. As we better understand the mechanisms by which specific proteins contribute to neurotoxicity, we can identify appropriate therapeutic targets and tailor treatments for individual patients based on their unique pathological profiles.

Moreover, the advances in imaging technologies are allowing for a more comprehensive view of neurodegenerative disease progression. These insights can potentially lead to the development of novel drug candidates that interfere with the aggregation processes of these critical proteins. For example, targeting the interactions between amyloid-β and tau may yield therapeutic strategies that can influence disease outcomes positively.

Overall, the strides made in PET imaging are opening new avenues for research and clinical interventions. With ongoing investigations into neurodegenerative diseases, the promise of personalized medicine becomes increasingly achievable. The potential of these imaging technologies to provide real-time assessments of therapeutic efficacy marks a significant step forward in neurodegenerative disease research.

As researchers continue to unravel the complexities of these diseases, the synergy between imaging techniques and molecular biology will undoubtedly drive the field forward. The quest for innovative solutions to combat neurodegenerative diseases is an incredibly interdisciplinary endeavor, requiring collaboration among neuroscientists, pharmacologists, and clinicians.

The future of neurodegenerative disease research is bright, with PET imaging poised to play a pivotal role in shaping our understanding of the underlying mechanisms and guiding the development of novel therapeutic approaches. As we strive to improve diagnostic capabilities and treatment modalities, the importance of these advancements in imaging cannot be overstated. The potential to visualize and characterize neurodegenerative pathologies in vivo will transform how we understand and ultimately address these debilitating diseases.

In summary, the review of advances in PET imaging technologies highlights the significance of visualizing neurodegenerative proteinopathies. The ongoing innovations in this field promise to bring profound changes in diagnosing and treating conditions like Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders, allowing health professionals to offer better care for affected individuals, and providing researchers with new insights into the fundamental mechanisms driving neurodegeneration.

Subject of Research: Advances in PET imaging of neurodegenerative diseases

Article Title: Advances in PET imaging of protein aggregates associated with neurodegenerative disease.

Article References:

Higuchi, M., Tagai, K., Takahata, K. et al. Advances in PET imaging of protein aggregates associated with neurodegenerative disease. Nat Rev Neurol 21, 506–522 (2025). https://doi.org/10.1038/s41582-025-01126-2

Image Credits: AI Generated

DOI:

Keywords: Neurodegenerative diseases, PET imaging, amyloid-β, tau, α-synuclein, TDP43, FUS, protein aggregates, neurotoxicity, diagnostics, therapeutics.

At the crux of the study lies α-synuclein, a neuronal protein long implicated in the pathogenesis of Parkinson’s disease (PD). Under normal physiological conditions, α-synuclein plays critical roles in synaptic transmission and neuronal plasticity. However, its aberrant accumulation and aggregation into insoluble fibrils characterize the pathological hallmark of PD, contributing to the degeneration of dopaminergic neurons. The new findings elucidate how chronic psychological stress acts as a potent upstream regulator of α-synuclein expression, thereby exacerbating neuronal dysfunction and behavioral abnormalities reminiscent of both depression and Parkinsonism.

The research team employed an array of sophisticated molecular biology techniques alongside behavioral assays in animal models to simulate prolonged stress conditions akin to those experienced in human chronic stress scenarios. Remarkably, the animals exhibited a constellation of behavioral deficits including reduced exploratory activity, anhedonia-like symptoms, and motor impairments mirroring early Parkinsonian signs such as bradykinesia and rigidity. Molecular analyses revealed a significant upregulation of α-synuclein in key brain regions responsible for emotion regulation and motor control, including the substantia nigra and prefrontal cortex, underscoring a potential mechanistic link between stress and neurodegenerative progression.

Underlying these phenomena is a complex interplay of stress-responsive signaling cascades that mediate α-synuclein gene transcription and post-translational modification. The study highlights the enhanced activation of hypothalamic-pituitary-adrenal (HPA) axis under chronic stress conditions, leading to elevated glucocorticoid levels that influence neuronal gene expression. Intriguingly, glucocorticoid receptor binding sites have been identified in the promoter region of the α-synuclein gene, implicating a transcriptional regulation axis through which stress hormones might upregulate α-synuclein synthesis, thereby seeding pathological aggregation.

Beyond transcriptional control, the research also sheds light on stress-induced impairment of proteostasis mechanisms responsible for α-synuclein degradation. Proteasomal and lysosomal pathways, crucial for maintaining intracellular protein homeostasis, appear compromised under chronic stress, contributing to the accumulation of misfolded α-synuclein species. This proteostatic failure likely potentiates the neurotoxic cascade, fostering an intracellular environment conducive to α-synuclein oligomerization and fibrillization.

Importantly, the study delineates the bidirectional relationship between α-synuclein pathology and depressive behaviors. While PD is traditionally characterized by motor symptoms, psychiatric manifestations including depression are increasingly recognized as prodromal or comorbid features. The authors report that α-synuclein overexpression correlates with synaptic deficits in glutamatergic and dopaminergic neurotransmission within limbic circuits, perturbations that may underlie mood dysregulation. This dual impact on motor and affective domains highlights a shared molecular substrate influenced by chronic stress, drawing a unified pathophysiological framework.

The translational relevance of these findings cannot be overstated. As chronic stress is an ever-present factor in modern life and a known risk factor for neuropsychiatric diseases, uncovering its direct involvement in α-synuclein-mediated neurodegeneration opens avenues for early intervention strategies. Therapeutic approaches targeting stress management, glucocorticoid signaling modulation, or enhancement of protein degradation pathways may hold promise in mitigating or delaying Parkinson’s disease onset and ameliorating depressive symptoms. Moreover, the research sets the stage for biomarker discovery efforts to identify individuals at heightened risk due to stress-induced molecular alterations.

Notably, this work also raises important considerations about the environmental and lifestyle contributions to neurodegenerative diseases. In a field mostly focused on genetic predispositions, the demonstration that chronic stress can potentiate α-synuclein pathology underscores the significant impact of epigenetic and environmental factors. It prompts a reevaluation of current paradigms surrounding Parkinson’s and related disorders, advocating for integrative models incorporating psychosocial variables alongside molecular genetics.

The study extensively utilized immunohistochemical analysis, RNA sequencing, and behavioral phenotyping to characterize the effects of chronic stress on α-synuclein dynamics. These multifaceted approaches allowed for a comprehensive investigation from molecular changes at the synapse to whole-animal phenotypic outcomes. The correlation between elevated α-synuclein levels and specific behavioral deficits strengthens the causal inference, establishing a robust link within the biological cascade from stress exposure to neurodegeneration.

Further investigation into the temporal dynamics reveals that the upregulation of α-synuclein occurs relatively early in the chronic stress timeline, suggesting that α-synuclein modulation may serve as an initial trigger rather than a downstream consequence. This timing offers a critical window for therapeutic intervention before irreversible neuronal loss transpires. The reversibility of these changes, however, remains to be elucidated, warranting longitudinal studies to assess the long-term impact and potential for disease modification.

The authors also discuss the potential involvement of neuroinflammatory pathways as mediators between chronic stress and α-synuclein aggregation. Chronic stress is known to induce microglial activation and release of pro-inflammatory cytokines, which can exacerbate neuronal injury. The inflammatory milieu may thus act synergistically with protein aggregation to accelerate neurodegenerative cascades. This intersection between stress, inflammation, and proteinopathy represents a fertile ground for future therapeutic exploration.

In conclusion, this transformative study delineates a novel pathogenic axis whereby chronic psychological stress induces Parkinsonism and depression-like phenotypes via the upregulation of α-synuclein. By integrating behavioral neuroscience, molecular biology, and neurodegeneration research, the authors provide a compelling narrative linking environmental stressors to the molecular underpinnings of Parkinson’s disease. As the global burden of neurodegenerative disorders continues to rise, understanding and mitigating modifiable risk factors such as stress emerges as an urgent priority with significant clinical and societal implications.

Subject of Research: Chronic stress-induced molecular mechanisms leading to depression-like behaviors and Parkinsonism mediated by α-synuclein upregulation.

Article Title: Chronic stress induces depression-like behaviors and Parkinsonism via upregulating α-synuclein.

Article References:
Xia, D., Xiong, M., Yang, Y. et al. Chronic stress induces depression-like behaviors and Parkinsonism via upregulating α-synuclein. npj Parkinsons Dis. 11, 139 (2025). https://doi.org/10.1038/s41531-025-00998-x

Image Credits: AI Generated